Investments
4Portfolio Exits
1Partners & Customers
1About National Brain Tumor Society
National Brain Tumor Society (NBTS) is dedicated to help: empower individuals with information, online programs, caring support, and direct connections to others going through the same challenges; fund transformative research to lead more rapidly to new therapies for adult and pediatric brain tumors, and ultimately to cures; advocate for brain tumor patients, families, caregivers, healthcare professionals, and researchers.

Want to inform investors similar to National Brain Tumor Society about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest National Brain Tumor Society News
Nov 18, 2022
News Provided By Share This Article Levi Metheny has joined the 50/31 challenge to support the National Tumor Society by raising funds for brain tumor research. NEWTON, MA, UNITED STATES, November 17, 2022 / EINPresswire.com / -- Levi Metheny successfully completed the 50/31 challenge held by The National Brain Tumor Society (NBTS). The non-profit organization hosted a month-long fitness challenge to align with Brain Tumor Awareness Month in May. The challenge involves running 50 miles in 31 days in order to raise funds for brain tumor research. “I am humbled to participate in this challenge to raise awareness for a vital cause,” says Levi Metheny, a Sales Representative with the Dow Jones PIB Sales Team. “Through NBTS research, I believe we will continue to see progress in finding a cure for brain tumors.” Currently, there are an estimated 700,000 people in the United States living with primary brain tumor, and more than 88,000 cases are to be diagnosed in 2022, according to NBTS. The 50/31 challenge had over 170 runners and successfully raised $29,797 for NBTS as of March last year. The marathon encourages accountability, consistency, and pushing one’s mental and physical strength while contributing to an important issue. Levi Metheny attended the University at Albany where he earned his bachelor’s degree in Marketing and Management, was a three-year starter, and was named FCS Pre-Season All-American. He then went on to continue his education and received an MBA from Murray State University while completing his last season of football. Mr. Metheny also won the CAA All-Conference award and participated in volunteer initiatives through the school. When he was not on the field as a linebacker, he was supporting the team’s volunteer initiatives which included reading to elementary students and serving in local food pantries and soup kitchens. XXX To learn more about Levi Metheny, you can visit his Linkedin profile. Media Relations
National Brain Tumor Society Investments
4 Investments
National Brain Tumor Society has made 4 investments. Their latest investment was in Modifi Bio as part of their Seed VC on July 7, 2022.

National Brain Tumor Society Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
7/28/2022 | Seed VC | Modifi Bio | $6.4M | Yes | Connecticut Innovations, HighCape Partners, Ironwood Capital, National Brain Tumor Society, Undisclosed Investors, and Yale Ventures | 2 |
11/17/2021 | Series A | |||||
1/16/2019 | Grant | |||||
8/5/2010 | Grant - II |
Date | 7/28/2022 | 11/17/2021 | 1/16/2019 | 8/5/2010 |
---|---|---|---|---|
Round | Seed VC | Series A | Grant | Grant - II |
Company | Modifi Bio | |||
Amount | $6.4M | |||
New? | Yes | |||
Co-Investors | Connecticut Innovations, HighCape Partners, Ironwood Capital, National Brain Tumor Society, Undisclosed Investors, and Yale Ventures | |||
Sources | 2 |
National Brain Tumor Society Portfolio Exits
1 Portfolio Exit
National Brain Tumor Society has 1 portfolio exit. Their latest portfolio exit was Forte Biosciences on April 13, 2017.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
4/13/2017 | IPO | Public | 1 |
Date | 4/13/2017 |
---|---|
Exit | IPO |
Companies | |
Valuation | |
Acquirer | Public |
Sources | 1 |
National Brain Tumor Society Partners & Customers
1 Partners and customers
National Brain Tumor Society has 1 strategic partners and customers. National Brain Tumor Society recently partnered with Yale Cancer Center on February 2, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
2/22/2022 | Partner | United States | 14:03 ET National Brain Tumor Society Launches DNA Damage Response Consortium with Yale NEWTON , Mass. , Feb. 22 , 2022 / PRNewswire / -- Today , the National Brain Tumor Society announced the launch of its new flagship research initiative , the DNA Damage Response Consortium , in partnership with Yale Cancer Center . | 3 |
Date | 2/22/2022 |
---|---|
Type | Partner |
Business Partner | |
Country | United States |
News Snippet | 14:03 ET National Brain Tumor Society Launches DNA Damage Response Consortium with Yale NEWTON , Mass. , Feb. 22 , 2022 / PRNewswire / -- Today , the National Brain Tumor Society announced the launch of its new flagship research initiative , the DNA Damage Response Consortium , in partnership with Yale Cancer Center . |
Sources | 3 |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.